Literature DB >> 6519158

Amiodarone kinetics after single i.v. bolus and multiple dosing in healthy volunteers.

E Riva, L Aarons, R Latini, P Neyroz, R Urso.   

Abstract

We studied three healthy volunteers after a single i.v. bolus of amiodarone, during 1 month of chronic oral dosing and after the discontinuation of the drug. Blood concentrations of amiodarone declined rapidly in a bi-exponential fashion after i.v. bolus. The terminal half-life ranged from 10 to 17 h; after discontinuation of chronic treatment the terminal half-lives were 8-21 days. The i.v. data, the trough levels during multiple dosing and the washout phase could be simultaneously fitted using a triexponential equation. The subjects were carefully monitored for cardiac and thyroid function. One subject had to stop taking amiodarone because of profound bradycardia. A reduction of serum TT3 and FT3 concentrations and an increase of serum rT3 and FT4 was found.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519158     DOI: 10.1007/bf00549600

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Amiodarone distribution in human tissues after sudden death during Holter recording.

Authors:  A P Maggioni; A Maggi; A Volpi; V D'Aranno; G Tognoni; P Giani
Journal:  Am J Cardiol       Date:  1983-07       Impact factor: 2.778

Review 2.  Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone.

Authors:  F I Marcus; G H Fontaine; R Frank; Y Grosgogeat
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749

3.  Pharmacokinetics of amiodarone after intravenous and oral administration.

Authors:  F Andreasen; H Agerbaek; P Bjerregaard; H Gøtzsche
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

4.  Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients.

Authors:  R J Flanagan; G C Storey; D W Holt; P B Farmer
Journal:  J Pharm Pharmacol       Date:  1982-10       Impact factor: 3.765

Review 5.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

6.  Amiodarone kinetics after oral doses.

Authors:  R Kannan; K Nademanee; J A Hendrickson; H J Rostami; B N Singh
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

7.  Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy.

Authors:  B N Singh; K Nademanee
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

8.  Pharmacokinetics of amiodarone in man.

Authors:  E Riva; M Gerna; R Latini; P Giani; A Volpi; A Maggioni
Journal:  J Cardiovasc Pharmacol       Date:  1982 Mar-Apr       Impact factor: 3.105

9.  Pharmacokinetics of amiodarone in rats.

Authors:  E Riva; M Gerna; P Neyroz; R Urso; I Bartosek; A Guaitani
Journal:  J Cardiovasc Pharmacol       Date:  1982 Mar-Apr       Impact factor: 3.105

10.  Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; W M Jackman; G V Naccarelli; K A Warfel; R L Rinkenberger; D P Zipes
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

View more
  5 in total

1.  Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction.

Authors:  Ryan S Funk; Jeffrey P Krise
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

2.  Effect of amiodarone on serum T4 and T3 levels in hyperthyroid patients treated with methimazole.

Authors:  O Van Reeth; C Decoster; J Unger
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Class III antiarrhythmics in overdose. Presenting features and management principles.

Authors:  E W Leatham; D W Holt; W J McKenna
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

4.  Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats.

Authors:  S J Weir; C T Ueda
Journal:  J Pharmacokinet Biopharm       Date:  1986-12

5.  Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects.

Authors:  A Selen; A W Kinkel; A C Darke; D S Greene; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.